<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01520701</url>
  </required_header>
  <id_info>
    <org_study_id>IPAC</org_study_id>
    <nct_id>NCT01520701</nct_id>
  </id_info>
  <brief_title>Impact of Applying a Bandage Skin Hydrogel on the Pains of the Head and Neck in Patients With Cancer of Head and Neck Treated With Radiotherapy</brief_title>
  <acronym>IPAC</acronym>
  <official_title>Impact of Applying a Bandage Skin Hydrogel on the Pains of the Head and Neck in Patients With Cancer of Head and Neck Treated With Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hope to get by reduced and delayed acute radiodermatitis following the&#xD;
      application of dressings to skin hydrogel Hydrosorb®, a reduction in head and neck pains and&#xD;
      improved quality of life of patients with head and neck cancer treated with concomitant&#xD;
      radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2012</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Actual">February 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of applying a bandage hydrogel skin on head and neck pains</measure>
    <time_frame>end of radiotherapy</time_frame>
    <description>Assessing the impact of applying a bandage hydrogel skin on head and neck pains in patients with cancer of head and neck treated with concomitant radiotherapy by evaluating the proportion of patients with a deterioration in three or more points to their score algia EVA rating scale at the end of treatment compared to that obtained at baseline (D0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluating the terms of issue of the treatment</measure>
    <time_frame>during radiotherapy weekly : 1 up to 7 weeks and at 1,3,6,12,18,24,30 and 36 months after radiotherapy</time_frame>
    <description>Evaluating the terms of issue of the treatment (number of interruptions, longer duration of treatment, dose reduction therapeutic influence of psychosocial factors) and quality of life for patients.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Ialuset® application</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm with application to the skin Ialuset ® cervical during radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bandage skin Hydrosorb</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm bandage skin hydrogel (Hydrotac®) on the skin cervical during radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>bandage skin Hydrotac®</intervention_name>
    <description>Patients randomized to the arm with bandage skin will benefit from the application of the bandage skin hydrogel (Hydrotac®) at least 5 hours per day for the duration of treatment (the first day last day of radiotherapy).</description>
    <arm_group_label>bandage skin Hydrosorb</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ialuset®</intervention_name>
    <description>Patients randomized to receive reference of the application of cervical Ialuset® on skin throughout the treatment period (the first day to last day of radiotherapy).</description>
    <arm_group_label>Ialuset® application</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient aged 18 years old&#xD;
&#xD;
          -  Carcinoma oral cavity, pharyngolaryngeal or without lymphadenopathy door&#xD;
&#xD;
          -  Patient treated by one of the following diagrams&#xD;
&#xD;
               -  radiotherapy alone&#xD;
&#xD;
               -  postoperative radiotherapy + / - sensitized platinum (cisplatin or carboplatin)&#xD;
&#xD;
               -  ar chemoradiation 5-FU and platinum (the Cetuximab is not allowed)&#xD;
&#xD;
               -  diagram organ preservation (induction chemotherapy and radiotherapy in&#xD;
                  responders)&#xD;
&#xD;
          -  Untreated patients&#xD;
&#xD;
          -  Patient should receive conventional radiotherapy or tomotherapy&#xD;
&#xD;
          -  Adapted stomatological care&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  WHO score &lt; 2&#xD;
&#xD;
          -  Patient stable, not having the time of the examination of evidence of recurrent or&#xD;
             progressive malignancy other&#xD;
&#xD;
          -  - For patients with an indication of chemotherapy combined with&#xD;
             radiotherapy,biological assessments compatible with chemotherapy:&#xD;
&#xD;
               -  WBC &gt; 3000/mm3, Polynuclear &gt; 2000/mm3,Platelets &gt; 150,000/mm3, Creatinine less&#xD;
                  than 2 times normal; Bilirubin less than 2.5 times normal&#xD;
&#xD;
          -  Patient fluent in French&#xD;
&#xD;
          -  Affiliation to a system of social security&#xD;
&#xD;
          -  Patient has given written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with a history of malignancy, outside a basal cell carcinoma or cervical&#xD;
             cancer treated and cured&#xD;
&#xD;
          -  Patient has at the time of examination signs of recurrence or other neoplasia scalable&#xD;
&#xD;
          -  Patient with a history of prior chemotherapy or radiation therapy with the exception&#xD;
             of the scheme of organ preservation (induction chemotherapy before radiation)&#xD;
&#xD;
          -  For patients with an indication of chemotherapy combined with radiotherapy,&#xD;
             contraindication to treatment with specific platinum (cisplatin or carboplatin) with&#xD;
             or without 5 Fluorouracil&#xD;
&#xD;
          -  Infectious diseases uncontrolled&#xD;
&#xD;
          -  Patient is pregnant or lactating or absence of contraception during their reproductive&#xD;
&#xD;
          -  Patient hypertensive unbalanced under antihypertensive treatment&#xD;
&#xD;
          -  Uncontrolled cardiac disease&#xD;
&#xD;
          -  Patients with renal or hepatic&#xD;
&#xD;
          -  Known allergy to any component of Ialuset ®&#xD;
&#xD;
          -  Patient deprived of liberty under guardianship&#xD;
&#xD;
          -  Any medical condition or psychological associate that could compromise the patient's&#xD;
             ability to participate in the study&#xD;
&#xD;
          -  Inability to undergo medical test for geographical, social or psychological&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David BLANCHARD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre François Baclesse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Audrey LASNE-CARDON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre François Baclesse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Maurice TUBIANA</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François BACLESSE</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de la Baie</name>
      <address>
        <city>Avranches</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Leonard de Vinci</name>
      <address>
        <city>Chambray les TOURS</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>centre hospitalier du Cotentin</name>
      <address>
        <city>Cherbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Guillaume Le Conquérant</name>
      <address>
        <city>Le Havre</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2012</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>head and neck cancer</keyword>
  <keyword>Hydrotac®</keyword>
  <keyword>radiodermatitis</keyword>
  <keyword>algia</keyword>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

